Showing results (41-50 of 66) with videos related to
Sort By:
Pageof 7
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
A novel PS1 gene mutation in a large Aboriginal kindredRachel Butler, B Lynn Beattie, Umamon Puang Thong, et al.Journal of Clinical Pathology|September 10, 2015
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trialSusan D Richman, Richard Adams, Phil Quirke, et al.Virchows Archiv : an International Journal of Pathology|April 28, 2019
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testingZandra C Deans, Rachel Butler, Melanie Cheetham, et al.The Lancet. Oncology|April 8, 2014
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trialHarpreet Wasan, Angela M Meade, Richard Adams, et al.BMC Cancer|August 11, 2018
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNACleo Keppens, Elisabeth M C Dequeker, Simon J Patton, et al.Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.Nature Nanotechnology|August 8, 2008
Formation and enhanced biocidal activity of water-dispersable organic nanoparticlesHaifei Zhang, Dong Wang, Rachel Butler, et al.Journal of Clinical Pathology|March 8, 2022
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testingSusan D Richman, Gemma Hemmings, Helen Roberts, et al.CHEST Critical Care|July 13, 2026
Black Surrogate Decision-Makers' Perspectives on the American Thoracic Society and Society for Critical Care Medicine Statement on Shared Decision-Making in ICUsJulia A Bulova, Kimberly Rak, Karen Bullock, et al.The Lancet. Gastroenterology & Hepatology|December 20, 2017
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trialRichard Adams, Ewan Brown, Louise Brown, et al.Pageof 7